Advanced Search

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 1) (No. PB 4 of 2012)

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now for only USD$40 per month.
 
PB 4 of 2012
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 1)
 
National Health Act 1953
___________________________________________________________________________
 
I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.
Dated 16 February 2012
 
 
 
 
 
 
 
 
 
 
 
FELICITY McNEILL
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
___________________________________________________________________
 
 
 
 
 
1              Name of Instrument
 
(1)                This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 1).
 
(2)                This Instrument may also be cited as PB 4 of 2012.
 
2             Commencement
                This Instrument commences on 1 March 2012.
3              Amendments to PB 79 of 2011
                      Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).
 
 
Schedule 1                   Amendments
 
[1]    Schedule 1 Part 1, entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 10 mg in 5 mL with manner of administration Injection/intravesical and brand Epirubicin Ebewe
substitute:
Epirubicin
Solution for injection containing epirubicin hydrochloride 10 mg in 5 mL
Injection/ intravesical
Epirubicin Actavis 10
TA
MP
 
D

 
 
 
Epirubicin Ebewe
SZ
MP
 
D

 
[2]    Schedule 1 Part 1, entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 100 mg in 50 mL with manner of administration Injection/intravesical and brand Epirubicin Ebewe
substitute:
 
Solution for injection containing epirubicin hydrochloride 100 mg in 50 mL
Injection/ intravesical
Epirubicin Actavis 100
TA
MP
 
D

 
 
 
Epirubicin Ebewe
SZ
MP
 
D

 
[3]    Schedule 1 Part 1, entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 20 mg in 10 mL with manner of administration Injection/intravesical and brand Pharmorubicin Solution
substitute:
 
Solution for injection containing epirubicin hydrochloride 20 mg in 10 mL
Injection/ intravesical
Epirubicin Actavis 20
TA
MP
 
D

 
 
 
Pharmorubicin Solution
PF
MP
 
D

 
[4]    Schedule 1 Part 1, after entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL with manner of administration Injection/intravesical and brand DBL Epirubicin Hydrochloride Injection
insert in the columns in the order indicated:
 
 
 
Epirubicin Actavis 200
TA
MP
 
D
 
[5]    Schedule 1 Part 1, entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL with manner of administration Injection/intravesical and brand Epirubicin Ebewe
substitute:
 
Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL
Injection/ intravesical
Epirubicin Actavis 50
TA
MP
 
D

 
 
 
Epirubicin Ebewe
SZ
MP
 
D

 
 
[6]    Schedule 1 Part 1, entry for Gemcitabine
omit from the column headed “Circumstances” (all instances):
C1193
C1194

C1740
C2069

C2141
C3889

C3890
C3906

C3913
C3914

 
[7]    Schedule 1 Part 1, after entry for Gemcitabine in the form Powder for I.V. infusion 200 mg (as hydrochloride) with manner of administration Injection and brand Gemzar
insert in the columns in the order indicated:
 
 
Solution concentrate for I.V. infusion 1 g (as hydrochloride) in 25 mL
Injection
Gemcitabine Ebewe
SZ
MP
 
D
 
[8]    Schedule 1 Part 1, after entry for Gemcitabine in the form Solution concentrate for I.V. infusion 1000 mg (as hydrochloride) in 100 mL
insert in the columns in the order indicated:
 
 
Solution concentrate for I.V. infusion 2 g (as hydrochloride) in 50 mL
Injection
Gemcitabine Ebewe
SZ
MP
 
D
 
[9]    Schedule 1 Part 1, after entry for Gemcitabine in the form Solution concentrate for I.V. infusion 200 mg (as hydrochloride) in 20 mL
insert in the columns in the order indicated:
 
 
Solution concentrate for I.V. infusion 200 mg (as hydrochloride) in 5 mL
Injection
Gemcitabine Ebewe
SZ
MP
 
D
 
[10]  Schedule 4, omit entry for Gemcitabine
 
Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 
See http://www.frli.gov.au.